Experts from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, recently published a review examining the challenges of diagnosing and treating leukemia and lymphoma during pregnancy. Rutgers Cancer Institute is a leader nationally and globally in these highly complex scenarios. Because these cancers may require chemotherapy, treatment decisions must carefully balance risks to both the mother and baby. The review underscores the need for a multidisciplinary approach involving oncologists, obstetricians, and maternal-fetal medicine specialists. It also explores the latest treatment strategies, including targeted therapies and immunotherapy, and provides expert recommendations on navigating these complex cases. Read the full review published in Seminars in Perinatology: PubMed – Managing Blood Cancers During Pregnancy
Authors of the review include Adam S. Zayac, MD and Ogechukwu Egini, MD, MS hematologist/oncologists in the Leukemia/Lymphoma/Hematologic Malignancies program at Rutgers Cancer Institute and RWJBarnabas Health; Neil D. Palmisiano, MD, MS, system leader for Leukemia at RWJBarnabas Health and deputy director of Phase I Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute; and Andrew M. Evens, DO, MBA, MSc, deputy director for Clinical Services and chief physician officer, Rutgers Cancer Institute and the Jack & Sheryl Morris Cancer Center and oncology lead for RWJBarnabas Health Medical Group, and system director of Medical Oncology, RWJBarnabas Health.
MEDIA CONTACTS:
Krista Didzbalis
732.507.8307
krista.didzbalis2@rwjbh.org